Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Paradigm Biopharmaceuticals Limited (PAR.AX)
AUD0.16
+0.00 (+0.00%)
AU ASX Healthcare Biotechnology
Address
500 Collins Street 3000
Melbourne, VIC, AU
Melbourne, VIC, AU
CEO
Paul John Rennie
Website
paradigmbiopharma.com
IPO
2015-08-19
ISIN AU000000PAR5
Also trades on
Australian Securities Exchange · PAR.AX (AUD)
Other OTC · PBIGF (USD)
Description
Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health. A central offering is an injectable formulation of pentosan polysulfate sodium, currently undergoing development for the treatment of conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, chikungunya, and acute respiratory distress syndrome. This company commenced operations in 2014.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.16
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
-0.02
Float Shares
403.10M
Free Float %
93.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -5.71% | -2.94% | -36.54% | -57.14% | -51.47% | -46.77% | -80.27% | -92.25% | -45.32% | -52.70% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.16
DCF (Unlevered)
0.06
-60.1%
DCF (Levered)
0.04
-75.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-21.73
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-20.8%
-
EPS growth Biotechnology: +29.7%+70.2% ★ Q4'25: +66.9% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-35,728.2% Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-48,535.6% Q4'25: -86,793.9% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-578.7% Q4'25: +1,140.8% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+7.2% Q4'25: +38.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: -0.01× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.98M
est: 3.00M (-0.5%)
|
—
est: 2.65M (-100.0%)
|
20.6K
est: 3.40M (-99.4%)
|
79.2K
est: 4.95M (-98.4%)
|
46.8K
est: 9.00M (-99.5%)
|
65.8K
est: 32.30M (-99.8%)
|
52.1K
est: 1.50M (-96.5%)
|
3.26M
3.26M – 3.26M
+117.3% YoY
|
3.26M
3.26M – 3.26M
+0.0% YoY
|
520.30M
520.30M – 520.30M
+15,860.1% YoY
|
| EBITDA |
-8.95M
est: -3.00M (-198.4%)
|
-15.70M
est: -2.65M (-492.4%)
|
-42.40M
est: -19.57M (-116.6%)
|
-46.82M
est: -38.23M (-22.5%)
|
-59.06M
est: -376.43M (+84.3%)
|
-64.54M
est: -2.22B (+97.1%)
|
-25.25M
est: -13.12B (+99.8%)
|
-3.26M
-3.26M – -3.26M
+100.0% YoY
|
-3.26M
-3.26M – -3.26M
+0.0% YoY
|
-520.30M
-520.30M – -520.30M
-15,860.1% YoY
|
| EBIT |
-8.96M
est: -3.00M (-198.7%)
|
-15.91M
est: -2.65M (-500.5%)
|
-42.61M
est: -19.46M (-118.9%)
|
-46.98M
est: -38.02M (-23.6%)
|
-58.94M
est: -374.34M (+84.3%)
|
-64.69M
est: -2.21B (+97.1%)
|
-25.30M
est: -13.05B (+99.8%)
|
-3.26M
-3.26M – -3.26M
+100.0% YoY
|
-3.26M
-3.26M – -3.26M
+0.0% YoY
|
-520.30M
-520.30M – -520.30M
-15,860.1% YoY
|
| Net Income |
-15.63M
est: -11.54M (-35.4%)
|
-12.30M
est: -21.56M (+43.0%)
|
-34.30M
est: -19.52M (-75.7%)
|
-39.25M
est: -38.13M (-2.9%)
|
-51.91M
est: -51.91M (+0.0%)
|
-58.65M
est: -58.65M (+0.0%)
|
-18.77M
est: -18.77M (+0.0%)
|
-31.45M
-31.45M – -31.45M
-67.5% YoY
|
-31.45M
-31.45M – -31.45M
+0.0% YoY
|
91.21M
91.21M – 91.21M
+390.0% YoY
|
| SGA |
3.83M
est: 562.42M (-99.3%)
|
4.17M
est: 496.81M (-99.2%)
|
9.59M
est: 637.41M (-98.5%)
|
8.85M
est: 927.99M (-99.0%)
|
7.39M
est: 1.69B (-99.6%)
|
6.77M
est: 6.06B (-99.9%)
|
5.13M
est: 281.21M (-98.2%)
|
611.16M
611.16M – 611.16M
+117.3% YoY
|
611.16M
611.16M – 611.16M
+0.0% YoY
|
97.54B
97.54B – 97.54B
+15,860.1% YoY
|
| EPS |
-0.11
est: -0.04 (-199.8%)
|
-0.06
est: -0.07 (+13.8%)
|
-0.16
est: -0.14 (-12.3%)
|
-0.16
est: -0.20 (+21.7%)
|
-0.18
est: -0.18 (+2.1%)
|
-0.20
est: -0.20 (+0.5%)
|
-0.06
est: -0.06 (+6.7%)
|
-0.10
-0.10 – -0.10
-56.3% YoY
|
-0.10
-0.10 – -0.10
+0.0% YoY
|
0.29
0.29 – 0.29
+390.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-16.01M
OE per share TTM
-0.04
Owner's Yield
-23.45%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
88.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 6.5K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-21.1K
Shares Outstanding
433.39M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul John Rennie MSTC | Founder, MD & Executive Chairman | 1M | male |
| Donna L. Skerrett | Chief Medical Officer | 437.1K | — |
| Michael Imperiale | Global Head of Drug Safety & MPS | — | — |
| Mukesh Ahuja | Global Clinical Head of OA | — | — |
| Ravi Krishnan | Chief Scientific Officer | — | — |
| Abby Macni Niven | Company Secretary & Chief Financial Officer | — | female |
| Simon White | Director of Investor Relations | — | male |
| Beverley Huttmann | Commercial Head | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PAR.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
